Supplementary appendix

Abstract

This appendix formed part of the original submission and has been peer reviewed.We post it as supplied by the authors. Supplement to: Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.

Lancet Oncol 2022; published online April 27. https://doi.org/10.1016/S1470-2045(22)00212-1.